Clinical Trials
45 trialsNCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT02457156 2025-03-13
PANasta
University of Liverpool
Phase 3 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04871204 2024-10-31
OTIS
Karolinska University Hospital
Phase 2 Completed
NCT02381249 2023-11-27
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
St. James's Hospital, Ireland
Phase NA Completed
NCT02385617 2023-11-27
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
St. James's Hospital, Ireland
Phase NA Completed
NCT06080204 2023-10-18
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Phase NA Completed
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003057 2023-06-18
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003283 2023-06-15
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT05682209 2023-01-18
The Effect of Octreotide on Wound Drainage After Mastectomy
University College Hospital, Ibadan
Phase 4 Completed
NCT01229943 2022-08-04
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT03734627 2021-08-16
EndoGut
St. James's Hospital, Ireland
Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT04129255 2020-09-10
CSMS99
National Cancer Institute, Naples
Phase 2 Completed
NCT00002864 2020-04-01
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00226967 2020-01-27
Stress, Diurnal Cortisol, and Breast Cancer Survival
Stanford University
Completed
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT00182754 2017-04-11
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00332969 2017-03-31
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Novartis
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT00002779 2016-12-15
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00033605 2016-07-13
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00075868 2015-11-17
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT01029275 2014-07-31
SAPORO
University Hospital, Rouen
Phase NA Completed
NCT00008073 2013-12-19
Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
University of Pittsburgh
Phase 1 Completed
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed
NCT00004895 2012-06-06
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Northwestern University
Phase 2 Completed
NCT00257426 2012-02-14
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00332696 2011-09-23
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Novartis
Phase 2 Completed
NCT00005906 2010-04-30
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00250796 2010-01-07
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
University of New Mexico
Phase 2 Completed
NCT00050635 2009-11-19
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Novartis
Phase 4 Completed
NCT00616408 2008-02-15
Prediction of Tumor Shrinkage in Acromegaly
Federico II University
Completed
NCT00386984 2006-10-12
Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
University Hospital Freiburg
Phase 3 Completed